Business Overview: IDEAYA Biosciences, Inc. (Nasdaq: IDYA)

---

Executive Summary

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company that designs targeted cancer therapies for molecularly-defined patient populations, using a synthetic lethality approach — pairing a drug with a specific genetic vulnerability so that cancer cells, but not healthy cells, die. The company has no approved products and generates no product revenue; its value lies entirely in a multi-program pipeline and a set of pharmaceutical partnerships that validate and help fund that pipeline.

IDEAYA's lead program, darovasertib, is advancing through three registrational trials in uveal melanoma, a rare eye cancer with few effective treatments. The company ended 2025 with roughly $1.05 billion in cash, equivalents, and marketable securities — which it says is enough to fund operations into 2030 — against a FY2025 net loss of $113.7 million (down sharply from $274.5 million in 2024, helped by partner payments and cost discipline).

---

1. Core Business Model & How They Work

IDEAYA does not sell a product; it builds and advances a pipeline of precision oncology drug candidates, monetizing them through licensing deals, milestone payments, and (eventually, if approved) direct commercialization.

[ Target/Biomarker Discovery (INQUIRE/HARMONY/DECIPHER) ] ➡️ [ Preclinical Candidate ] ➡️ [ Phase 1/2 Trials ] ➡️ [ Partner Co-Development / Licensing ] ➡️ [ Pivotal Trials ] ➡️ [ Approval & Commercialization ]

Key Operational Drivers

1. In-licensing + internal discovery hybrid: IDEAYA both develops candidates internally (via its discovery platforms) and in-licenses promising assets from larger players — darovasertib was in-licensed from Novartis, and IDE849 from Hengrui Pharma.
2. Risk-sharing partnerships: GSK funds 80% of the WRN program's development costs and 100% of the Pol Theta program's costs, letting IDEAYA advance two late-stage mechanisms without bearing their full cost.
3. Milestone and upfront economics: Deals with Hengrui ($75.0M upfront, up to $1.045B in total potential payments) and GSK (IDEAYA earned $7.0M on an IND clearance milestone in October 2024, with up to $10.0M more available) provide non-dilutive capital alongside equity raises.
4. Combination-therapy strategy: Several programs are being tested in combination with other companies' approved drugs (Gilead's Trodelvy, Merck's Keytruda, Pfizer's crizotinib), which can shorten the path to differentiated efficacy data.

---

2. Business Segments

IDEAYA operates as a single operating segment — clinical-stage biopharmaceutical research and development. A segment breakdown by drug program is not how the company reports financials, though its pipeline is naturally organized by target/mechanism (see Product Portfolio below).

---

3. Product Portfolio (Pipeline)

---

4. Competitive Landscape

IDEAYA faces larger, better-capitalized competitors in every program, a structural reality the company itself emphasizes:

• Uveal melanoma (darovasertib): Immunocore's approved Kimmtrak, Aura Biosciences, and Novartis's own DYP688 ADC program.
• MAT2A (IDE397): Servier, Insilico Medicine, and BeiGene all have competing MAT2A inhibitor programs.
• DLL3 (IDE849): Amgen's Imdelltra received accelerated approval in May 2024 and is the clear first-mover; several other DLL3 ADCs and radiopharmaceuticals are also in development.
• PARG / Pol Theta: Multiple companies have competing clinical and preclinical programs in both mechanisms.
• WRN (IDE275): Novartis's own HRO-761 is in Phase 1, making this a direct race against one of IDEAYA's own partners' broader pipeline.

         CLINICAL-STAGE ONCOLOGY POSITIONING
┌─────────────────────────────────────────────┐
│ High │  [Amgen Imdelltra]  [Immunocore Kimmtrak]│
│Clinical│      (approved, first-mover)            │
│ Stage│                                          │
│      │        [IDEAYA: darovasertib Ph2/3]      │
│      │   [IDEAYA: IDE397, IDE849, IDE161 Ph1/2]  │
│ Low  │  [IDEAYA: IDE892/IDE034/IDE251 preclinical]│
│      └────────────────────────────────────────►
│        Novel/Niche Target      Validated Target │
└─────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Strengths (The Moat)

• Deep discovery platform: The INQUIRE compound library (200,000+ molecules), HARMONY machine-learning engine, and DECIPHER dual-CRISPR synthetic lethality library (built with UC San Diego) give IDEAYA a repeatable way to find new synthetic-lethal targets, not just a single drug bet.
• Validated partnerships: GSK, Hengrui, Gilead, Pfizer, and Merck have all entered into collaboration, licensing, or combination-supply agreements, each implicitly validating IDEAYA's science and sharing development risk and cost.
• Balance sheet runway: ~$1.05 billion in cash and investments, guided to last into 2030, is an unusually long runway for a clinical-stage biotech and reduces near-term dilution risk.
• Multiple near-term catalysts: Darovasertib's OptimUM-02 topline PFS data (expected around late March 2026) is a binary, near-term value-defining event.

Risks

1. Binary clinical risk: As with any clinical-stage biotech, a single trial failure (especially OptimUM-02) could materially impair the stock and the broader darovasertib franchise.
2. No product revenue: IDEAYA has no commercial product and depends entirely on partner payments, milestones, and capital markets access to fund ongoing losses ($113.7M net loss in FY2025 alone).
3. Crowded competitive fields: Several programs (DLL3, MAT2A, WRN) face competitors that are already approved or further along in development.
4. Partner dependency: A meaningful part of the pipeline (WRN, Pol Theta) is GSK-led; the Amgen IDE397 combination study being wound down in February 2025 shows partnerships can also be discontinued.
5. R&D cost growth: R&D expense rose from $294.7M to $314.7M year-over-year as the pipeline has expanded, a trend that will need to be managed carefully even against a large cash balance.

---

6. Financial Overview

---

7. Summary Conclusion

IDEAYA is a well-capitalized, platform-driven clinical-stage oncology company whose moat, to the extent one exists before any product is approved, comes from its discovery engine (INQUIRE/HARMONY/DECIPHER) and the roster of pharma partners (GSK, Hengrui, Gilead, Merck, Pfizer) who have chosen to co-develop or license its programs rather than build competing ones from scratch. The company's near-term fate is tied tightly to darovasertib's uveal melanoma trials, with OptimUM-02 topline data due around the end of March 2026 standing as the single most important catalyst; a long cash runway into 2030 buys time to absorb a setback in any one program, but does not remove the fundamental binary risk that comes with having no approved, revenue-generating product today.